C-terminally Truncated Fibrillin-1 Mouse Model for NPSCL
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transgenic non-human mammals engineered to have FBN1 mutations do not adequately reflect the symptoms of neonatal progeroid syndrome with congenital lipodystrophy (NPSCL), as they fail to accurately replicate the genetic and phenotypic characteristics of the condition.
Innovation Solution
A mouse model is developed with a mutation in the Fbn1 gene that results in a C-terminal truncation of the Fbn1 protein, leading to symptoms such as decreased body weight, decreased fat mass, increased food intake, and kyphosis, which are characteristic of NPSCL, by introducing specific mutations in the penultimate or final exon of the Fbn1 gene, disrupting the asprosin C-terminal cleavage product of pro-fibrillin-1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transgenic non-human mammals are engineered with FBN1 mutations, then the model should reflect Marfan syndrome symptoms, but the model fails to accurately represent NPSCL symptoms
Solution Approach 1:
The patent applies local quality by introducing a specific mutation location (penultimate exon of Fbn1 gene) that produces a C-terminal truncated protein. This localized genetic modification creates the specific NPSCL phenotype characterized by lipodystrophy and progeroid features, rather than the Marfan syndrome phenotype. The mutation position is precisely targeted to disrupt the asprosin C-terminal cleavage product while preserving other fibrillin-1 functions, thereby achieving accurate NPSCL phenotypic representation.
2Reliability
If the Fbn1 gene is mutated to produce C-terminal truncated protein, then NPSCL-like symptoms are exhibited, but the mutation disrupts the asprosin C-terminal cleavage product
Solution Approach 1:
The patent converts the harmful disruption of asprosin C-terminal cleavage into a beneficial research tool. By intentionally introducing the mutation that disrupts this cleavage process, the patent creates a model that accurately reproduces NPSCL pathology. The disruption itself becomes the mechanism for studying the disease, allowing researchers to investigate the relationship between impaired asprosin processing and NPSCL symptoms including lipodystrophy and progeroid features.
Data Source
Figure 1~2
Figure 3
Figure 4~5
AI summary
Provided are non-human animals comprising a mutation in the Fbnl gene to model neonatal progeroid syndrome with congenital lipodystrophy (NPSCL). Also provided are methods of making such non-human animal models. The non-human animal models can be used for screening compounds for activity in inhibiting or reducing NPSCL or ameliorating NPSCL- like symptoms or screening compounds for activity potentially harmful in promoting or exacerbating NPSCL as well as to provide insights in to the mechanism of NPSCL and potentially new therapeutic and diagnostic targets.